192 related articles for article (PubMed ID: 9702210)
1. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Lundberg BB
Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.
Watanabe M; Kawano K; Toma K; Hattori Y; Maitani Y
J Control Release; 2008 May; 127(3):231-8. PubMed ID: 18384903
[TBL] [Abstract][Full Text] [Related]
4. Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin.
Whitaker RD; Ingebrigtsen SG; Naderkhani E; Skar ML; Flaten GE
J Liposome Res; 2013 Dec; 23(4):298-310. PubMed ID: 23763495
[TBL] [Abstract][Full Text] [Related]
5. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
6. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
Flaten GE; Chang TT; Phillips WT; Brandl M; Bao A; Goins B
J Liposome Res; 2013 Mar; 23(1):70-81. PubMed ID: 23210622
[TBL] [Abstract][Full Text] [Related]
7. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.
Fang JY; Hung CF; Hua SC; Hwang TL
Ultrasonics; 2009 Jan; 49(1):39-46. PubMed ID: 18554679
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
9. Artificial lipids stabilized camptothecin incorporated in liposomes.
Maitani Y; Katayama S; Kawano K; Hayama A; Toma K
Biol Pharm Bull; 2008 May; 31(5):990-3. PubMed ID: 18451532
[TBL] [Abstract][Full Text] [Related]
10. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability.
Watanabe M; Kawano K; Yokoyama M; Opanasopit P; Okano T; Maitani Y
Int J Pharm; 2006 Feb; 308(1-2):183-9. PubMed ID: 16324807
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.
Daoud SS; Fetouh MI; Giovanella BC
Anticancer Drugs; 1995 Feb; 6(1):83-93. PubMed ID: 7756688
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells.
Acevedo-Morantes CY; Acevedo-Morantes MT; Suleiman-Rosado D; RamÃrez-Vick JE
Drug Deliv; 2013 Nov; 20(8):338-48. PubMed ID: 24024505
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system.
Opanasopit P; Ngawhirunpat T; Chaidedgumjorn A; Rojanarata T; Apirakaramwong A; Phongying S; Choochottiros C; Chirachanchai S
Eur J Pharm Biopharm; 2006 Nov; 64(3):269-76. PubMed ID: 16870407
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
16. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
Joguparthi V; Xiang TX; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
[TBL] [Abstract][Full Text] [Related]
17. Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions.
Zhao YX; Hua HY; Chang M; Liu WJ; Zhao Y; Liu HM
Int J Pharm; 2010 Jun; 392(1-2):64-71. PubMed ID: 20302926
[TBL] [Abstract][Full Text] [Related]
18. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
19. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
Xiao X; Cushman M
J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
[TBL] [Abstract][Full Text] [Related]
20. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.
Bom D; Curran DP; Zhang J; Zimmer SG; Bevins R; Kruszewski S; Howe JN; Bingcang A; Latus LJ; Burke TG
J Control Release; 2001 Jul; 74(1-3):325-33. PubMed ID: 11489514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]